Left ventricular dyssynchrony is associated with reduced heart rate variability in familial amyloidotic polyneuropathy

Zhao, Ying; Hörnsten, Rolf; Lindqvist, Per; Wiklund, Urban; Suhr, Ole B.; Henein, Michael Y.

doi:10.1016/j.ijcard.2010.10.015

Cited by 7 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, OL-HDF for 24 months improved autonomic neuropathy measured by HRV analysis. It is well known that many patients with systemic amyloidosis have autonomic neuropathy and they show abnormal HRV [28] , [29] . Most uremic patients have high β2-MG concentration and this causes uremic amyloidosis.…”

Section: Discussionmentioning

confidence: 99%

The effect of on-line hemodiafiltration on heart rate variability in end-stage renal disease

Park

Bae

Lee

et al. 2013

Kidney Research and Clinical Practice

View full text Add to dashboard Cite

BackgroundThe autonomic nervous system plays a central role in the maintenance of hemodynamic stability. Cardiac autonomic dysfunction may result in serious complications, such as sudden cardiac death. Heart rate variability (HRV) is significantly reduced in patients undergoing chronic hemodialysis (HD). The aim of this study was to evaluate the effect of on-line hemodiafiltration (OL-HDF) on the autonomic nervous system in chronic HD patients.MethodsForty chronic HD patients were prospectively studied. The participants were divided into conventional HD and OL-HDF groups. They received regular high-flux HD or OL-HDF for 4-hour sessions, three times a week. Time-and frequency-domain measures of the 24-hour HRV were analyzed during the interdialytic period prior to postdilution OL-HDF and every 6 months for 24 months. The 7-year survival was also evaluated.ResultsAmong the 40 participants, 15 patients in the HD group and 11 patients in the OL-HDF group completed the study. There was no difference in the baseline characteristics. After 24 months of treatment, β2-microglobulin concentration decreased (from 33.4±15.2 mg/dL to 28.4±6.2 mg/dL, P =0.02) in the OL-HDF group, while there was no change in the HD group. In the HRV analysis, the frequency-domain HRV parameters increased significantly compared with baseline in the OL-HDF group [natural logarithmic high frequency (lnHF), 3.15±3.36 ms2 vs. 4.42±3.81 ms2; ln low frequency (LF), 3.56±3.17 ms2 vs. 4.78±3.99 ms2; ln very low frequency (VLF), 4.90±4.62 ms2 vs. 6.38±5.54 ms2; LF/HF ratio, 1.4±0.4 vs. 2.5±0.1]. The survival rate was similar between the groups.ConclusionThis study shows that OL-HDF improved autonomic nervous system dysfunction in chronic HD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of on-line hemodiafiltration on heart rate variability in end-stage renal disease

Park

Bae

Lee

et al. 2013

Kidney Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Decreased heart rate variability in FAP appears to be associated with shortened LV filling time and prolonged total isovolumic time reflecting ventricular dyssynchrony despite normal QRS complex [44]. Additionally, ATTR-CA patients often become pacemaker dependent.…”

Section: Considerations For Pacemaker and Cardioverter–defibrillator mentioning

confidence: 99%

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

et al. 2014

View full text Add to dashboard Cite

Transthyretin-cardiac amyloidoses (ATTR-CA) are an underdiagnosed but increasingly recognized cause of heart failure. Extracellular deposition of fibrillary proteins into tissues due to a variety of inherited transthyretin mutations in ATTRm or due to advanced age in ATTRwt eventually leads to organ failure. In the heart, amyloid deposition causes diastolic dysfunction, restrictive cardio-myopathy with progressive loss of systolic function, arrhythmias, and heart failure. While traditional treatments have consisted of conventional heart failure management and supportive care for systemic symptoms, numerous disease-modifying therapies have emerged over the past decade. From organ transplantation to transthyretin stabilizers (diflunisal, tafamidis, AG-1), TTR silencers (ALN-ATTR02, ISIS-TTR(Rx)), and degraders of amyloid fibrils (doxycycline/TUDCA), the potential for effective transthyretin amyloid therapy is greater now than ever before. In light of these multiple agents under investigation in human clinical trials, clinicians should be familiar with the systemic cardiac amyloidoses, their differing pathophysiology, natural histories, and unique treatment strategies.

show abstract

Restrictive Cardiomyopathy

Alizadehasl¹,

Sadeghpour²

2018

Case-Based Textbook of Echocardiography

View full text Add to dashboard Cite

Left ventricular dyssynchrony is associated with reduced heart rate variability in familial amyloidotic polyneuropathy

Cited by 7 publications

References 23 publications

The effect of on-line hemodiafiltration on heart rate variability in end-stage renal disease

The effect of on-line hemodiafiltration on heart rate variability in end-stage renal disease

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

Restrictive Cardiomyopathy

Contact Info

Product

Resources

About